Skip to Main Content Skip to Site Map Skip to Accessibility Statement

Sodium Valproate & Topiramate Monitoring Statistics to September 2026

19 November 2026

The following report Sodium Valproate & Topiramate Monitoring Statistics to September 2026 has been published today as part of the General Pharmaceutical Services and Prescribing Statistics for Northern Ireland publication schedule.  This report, produced in accordance with the Code of Practice for Statistics, contributes to the monitoring of the effectiveness of actions to ensure safe and appropriate use of prescribed Sodium Valproate and Topiramate in Northern Ireland.

This quarterly series combines the previously separate reports of Sodium Valproate and Topiramate monitoring into a singular release, with two sets of tables and a single interactive dashboard and can be accessed on the BSO website by clicking on the following link: Sodium Valproate & Topiramate Monitoring – Business Services Organisation (BSO) Website

The Sodium Valproate and Topiramate Monitoring Dashboard presents the figures of the five indicators contained within the published tables in interactive visuals. This interactive dashboard allows users to easily select between medicine of interest and numerous variables in order to focus on specific areas of interest, such as age group, gender or area in each of the five indicators.

A key facts summary of the main findings of each report is below.

Infographic showing prescribing and dispensing trends for Sodium Valproate and Topiramate in Northern Ireland to September 2026. Among people aged 0-54, 719 females and 2,265 males were prescribed Sodium Valproate, while 815 females and 406 males were prescribed Topiramate. Since monitoring began, Sodium Valproate prescribing decreased by 53% for females and 31% for males since April 2019. Topiramate prescribing decreased by 32% for females and 9% for males since April 2023. Between July and September 2026, 11 females and 32 males under 55 started Sodium Valproate, while 32 females and 32 males started Topiramate.

Infographic showing prescribing rates and HSC Trust comparisons for Sodium Valproate and Topiramate in Northern Ireland to September 2026. The rate per 1,000 patients under 55 prescribed Sodium Valproate was 1.03 for females and 3.06 for males. The equivalent rate for Topiramate was 1.17 for females and 0.55 for males. The percentage of patients aged 13-44 who were female was 3.8% to 5.9% across Trusts for Sodium Valproate and 14.9% to 21.3% for Topiramate, with the highest proportions recorded in the Northern Trust and the lowest in the Belfast Trust for Sodium Valproate and Western Trust for Topiramate.